BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37373743)

  • 21. Insulin-like growth factor binding protein (IGFBP)-3-bound IGF-I and IGFBP-3-bound IGF-II in growth hormone deficiency.
    Belgorosky A; Rivarola MA
    Horm Res; 1999; 52(2):60-5. PubMed ID: 10681634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition.
    Rohrmann S; Grote VA; Becker S; Rinaldi S; Tjønneland A; Roswall N; Grønbæk H; Overvad K; Boutron-Ruault MC; Clavel-Chapelon F; Racine A; Teucher B; Boeing H; Drogan D; Dilis V; Lagiou P; Trichopoulou A; Palli D; Tagliabue G; Tumino R; Vineis P; Mattiello A; Rodríguez L; Duell EJ; Molina-Montes E; Dorronsoro M; Huerta JM; Ardanaz E; Jeurnink S; Peeters PH; Lindkvist B; Johansen D; Sund M; Ye W; Khaw KT; Wareham NJ; Allen NE; Crowe FL; Fedirko V; Jenab M; Michaud DS; Norat T; Riboli E; Bueno-de-Mesquita HB; Kaaks R
    Br J Cancer; 2012 Feb; 106(5):1004-10. PubMed ID: 22315049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis.
    Guz M; Jeleniewicz W; Cybulski M; Kozicka J; Kurzepa J; Mądro A
    Biomed Rep; 2021 Jan; 14(1):10. PubMed ID: 33235725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum cytokine profiles in patients with pancreatic cancer and chronic pancreatitis.
    Lanki M; Mustonen H; Salmi M; Jalkanen S; Haglund C; Seppänen H
    Pancreatology; 2023 Sep; 23(6):657-662. PubMed ID: 37468364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
    McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
    Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children.
    Smith WJ; Nam TJ; Underwood LE; Busby WH; Celnicker A; Clemmons DR
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1294-9. PubMed ID: 7521346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
    Mofid MR; Gheysarzadeh A; Bakhtiyari S
    Pancreatology; 2020 Oct; 20(7):1442-1450. PubMed ID: 32830034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The insulin-like growth factor binding protein-3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis.
    Gheysarzadeh A; Bakhtiari H; Ansari A; Emami Razavi A; Emami MH; Mofid MR
    J Cell Physiol; 2019 Dec; 234(12):23537-23546. PubMed ID: 31165486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
    Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
    Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer.
    Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
    Tumour Biol; 2014 Apr; 35(4):3125-32. PubMed ID: 24254307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle.
    Thierry van Dessel HJ; Chandrasekher Y; Yap OW; Lee PD; Hintz RL; Faessen GH; Braat DD; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1224-31. PubMed ID: 8772603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery.
    Lee DY; Yang DH; Kang CW; Kim SJ; Joo CU; Cho SC; Kim JS
    J Korean Med Sci; 1997 Feb; 12(1):32-9. PubMed ID: 9142657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
    Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
    World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus.
    Siahpush SH; Vaughan TL; Lampe JN; Freeman R; Lewis S; Odze RD; Blount PL; Ayub K; Rabinovitch PS; Reid BJ; Chen C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2387-95. PubMed ID: 18006928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics.
    Lassarre C; Duron F; Binoux M
    J Clin Endocrinol Metab; 2001 May; 86(5):1942-52. PubMed ID: 11344189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin-like growth factor binding protein 3.
    Juul A; Skakkebaek NE
    J Pediatr; 1997 Feb; 130(2):197-204. PubMed ID: 9042120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of insulin-like growth factor-II and insulin-like growth factor binding proteins during Caco-2 cell proliferation and differentiation.
    Park JH; Corkins MR; Vanderhoof JA; Caruso NM; Hrbek MJ; Schaffer BS; Slentz DH; McCusker RH; MacDonald RG
    J Cell Physiol; 1996 Feb; 166(2):396-406. PubMed ID: 8592000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.